Boehringer Ingelheim decided to discontinue the long-term extension trial, CONNEX-X, effective immediately. Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health.
the long-term extension study of iclepertin (CONNEX-X; ClinicalTrials.gov Identifier: NCT05211947) has been discontinued. “While these findings are disappointing, we remain dedicated to finding ...
4–6 Boehringer Ingelheim decided to discontinue the long-term extension trial, CONNEX-X, effective immediately. 13 Boehringer Ingelheim is a biopharmaceutical company active in both human and ...
Social network X is trying to capitalize on the uncertainty surrounding ByteDance apps like TikTok and Lemon8 by launching a dedicated vertical video feed. The company is adding a video tab in the ...
Jess started her career at TechRadar, covering news and hardware reviews. Meta, Google, TikTok, and X have each pledged to European lawmakers that they will do more to prevent and remove illegal ...
X has launched a new video tab for US users after TikTok was banned. Industry analysts estimate this strategic move could help X capture a significant portion of TikTok’s 170 million US user ...
X, formerly Twitter, debuted a new feature for its US users on Sunday — a tab dedicated to watching videos on the platform. "The Video Tab has arrived. LFG," X CEO Linda Yaccarino wrote in a ...
With the confirmation that Iclepertin has no effects, the long-term extension study (CONNEX-X) will also be discontinued. However, Iclepertin appears to have no significant issues regarding safety.
BRUSSELS, Jan 20 (Reuters) - Meta's (META.O), opens new tab Facebook, Elon Musk's X, Google's (GOOGL.O), opens new tab YouTube and other tech companies have agreed to do more to tackle online hate ...
4-6 Boehringer Ingelheim decided to discontinue the long-term extension trial, CONNEX-X, effective immediately. 13 Boehringer Ingelheim is a biopharmaceutical company active in both human and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results